Telix Pharmaceuticals Limited
TLXNASDAQHealthcareBiotechnology
As of Oct 22, 2026 close
- Market cap
- $3.40B
- P/E (TTM)
- 41.01
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $6.28$13.11
- Volume (live)
- -
- Avg. volume (3M)
- 473.24K
Telix Pharmaceuticals (TLX) Stock Price & Financial Analysis
Telix Pharmaceuticals Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $9.43 - $9.61 |
|---|---|
| 52-Week High | $13.11 |
| 52-Week Low | $6.28 |
| Open | $9.56 |
| Volume (last close) | 734.01K |
| Average Volume (3M) | 473.24K |
| Revenue (TTM) | 2.50B |
|---|---|
| Net Income (TTM) | 83.02M |
| Free Cash Flow (TTM) | -75.55M |
| EPS (TTM) | $0.24 |
| Profit Margin | 3.32% |
| Operating Margin | 2.96% |
| Return on Equity (ROE) | 17.02% |
| Debt to Equity | 0.83 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Last Dividend Ex-Date | Apr 18, 2006 |
| Market Cap | 3.40B |
|---|---|
| Shares Outstanding | 356.89M |
| P/E Ratio (TTM) | 41.01 |
| Price to Sales (P/S) | 1.36 |
| Price to Book (P/B) | 6.98 |
| EV/EBITDA | 25.80 |
| 50-Day MA | $11.49 |
|---|---|
| 200-Day MA | $9.83 |
| 1-Year Change | −12.32% |
Source: Market prices and company fundamentals. Data as of Oct 22, 2026. Data sources and methodology
Telix Pharmaceuticals at a Glance
As of the Oct 22, 2026 close, Telix Pharmaceuticals (TLX) has a market capitalization of $3.40B. The stock trades at 41.0× trailing earnings and 1.4× sales. Over the trailing twelve months it earned $83.02M on revenue of $2.50B (a 3.3% profit margin) and burned $75.55M of free cash flow. Revenue grew 53.9% year over year.
As of its latest reported balance sheet, it holds $251.91M in cash and securities against $405.02M of debt, a net debt position of $153.11M.
Telix Pharmaceuticals does not currently pay a dividend.
The share price is down 12.3% over the past year. At $9.54 (the Oct 22, 2026 close) it sits within its 52-week range of $6.28 to $13.11, below its 200-day moving average of $9.83.
Based on 1 professional analyst rating from the past 90 days, the consensus is Buy.
Frequently Asked Questions About Telix Pharmaceuticals
What is the current stock price for TLX?
As of the Oct 22, 2026 close, TLX stock trades at $9.54. The 52-week range is $6.28–$13.11, with a day range of $9.43–$9.61.
What is the P/E ratio for TLX?
As of the Oct 22, 2026 close, Telix Pharmaceuticals's trailing twelve-month (TTM) P/E ratio is 41.0, meaning investors pay $41.0 for every $1 of annual earnings. Telix Pharmaceuticals operates in the Healthcare sector.
Does TLX pay dividends?
Telix Pharmaceuticals does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for TLX?
Based on ratings from 1 professional analyst over the last 90 days, the consensus for TLX is Buy.
What is the market cap of TLX?
As of the Oct 22, 2026 close, Telix Pharmaceuticals's market capitalization is $3.40B, classifying it as a mid-cap company. Telix Pharmaceuticals operates in the Healthcare sector within the Biotechnology industry.